Introduction {#sec0005}
============

A pandemic of coronavirus disease-19 (COVID-19), which was first reported from Wuhan, China, in December 2019, is a global health threat ([@bib0140]). As of 18 May, 2020, 4,618,821 laboratory-confirmed cases have occurred, and the number is still increasing, with new epicenters ([@bib0110]).

The Chinese Center for Disease Control and Prevention reported that among 44,415 COVID-19 patients, more than 80% of the patients experienced mild disease. However, about 20% of the patients developed severe pneumonia or respiratory failure requiring mechanical ventilation ([@bib0115]). Although the recruitment of activated CD4^+^ and CD8^+^ T cells, decreased number of T cells, or increased expressions of cytotoxic granules have been reported ([@bib0080], [@bib0100], [@bib0120]), cell-mediated immune (CMI) responses in COVID-19 are not well understood. Understanding immunopathogenesis of progression of COVID-19 pneumonia is urgently needed to accelerate the development of therapeutic strategies.

Recent viral shedding kinetics studies showed that virus titers usually reach peak during the first week of illness, and decline during the second week of illness ([@bib0065], [@bib0145]). It is of note that patients with COVID-19 pneumonia may suddenly deteriorate 7‒10 days after illness onset, resulting in intensive care unit admission ([@bib0125], [@bib0135]). Therefore, we hypothesized that the immune response may play an important role for this temporally discrepant clinical deterioration in COVID-19 patients. In this study, we aimed to compare CMI responses between severe and mild COVID-19 patients at their first and third week of illness.

Methods {#sec0010}
=======

Patients and samples {#sec0015}
--------------------

We analyzed peripheral blood mononuclear cells (PBMCs) of laboratory-confirmed COVID-19 patients who had been treated at Seoul National University Hospital and Seoul National University Bundang Hospital. We collected peripheral blood samples from the patients at the first and third week of illness. A severe case was defined as having radiological pneumonia and having an oxygen saturation of 93% or less at room air during illness, while others were classified as a mild case ([@bib0115]). We also analyzed healthy volunteers' PBMCs to accurately assess COVID-19-related CMI responses. Institutional Review Boards of Seoul National University Hospital and Seoul National University Bundang Hospital approved the study (IRB No. 2003-011-1105 and B-2004/607-401), and waived the need for written informed consent of COVID-19 patients on public health grounds.

Flow cytometry {#sec0020}
--------------

PBMCs were purified from heparinized peripheral blood using a Ficoll--Histopaque gradient (1.077 g/mL; GE Healthcare Life Sciences, Piscataway, NJ, USA) ([@bib0040]). The PBMCs were then stored in liquid nitrogen after the addition of 50% fetal bovine serum (FBS), 10% dimethyl sulfoxide, and 40% RPMI-1640 (Life Technologies, Carlsbad, CA, USA) until assayed ([@bib0020]). Cryopreserved PBMCs were thawed and stained with following anti-human antibodies (Abs): V450--anti-HLA-DR, phycoerythrin (PE)--anti-CD25, fluorescein isothiocyanate (FITC)--anti-Ki-67, allophycocyanin--indotricarbocyanine (Cy7)--anti-CD8, FITC--anti-perforin, Alexa Fluor® 700--anti-granzyme B, Alexa Fluor® 647--anti-FoxP3, FITC--anti-IL-2, PE--anti-IL-4 from BD Biosciences (San Jose, CA, USA); eFluor® 450--anti-IL-7Rα, peridinin-chlorophyll proteins (PerCP)-cyanine 5.5 (Cy5.5)--anti-CD45RA, PE-Cy7--anti-interferon-γ (IFN-γ), eFluor® 660--anti-IL-17 from eBioscience (San Diego, CA, USA); Brilliant Violet (BV) 605--anti-CD4, Alexa Fluor® 700--anti-PD-1, BV605--anti-CD4, BV21--anti-CD8 from BioLegend (San Diego, CA, USA). FACS staining was performed as described previously ([@bib0020], [@bib0040]). A fluorescence minus one (FMO) control, a tube of cells stained with all fluorochromes used in the experiment except one, was used to determine the cut-off point between the background fluorescence and the positive population in this experiment.

For staining the effector molecules and the proliferation marker, cells were fixed with 2% paraformaldehyde and permeabilized with BD Perm/Wash™ buffer (BD Biosciences). Next, the cells were stained with fluorescently labeled Abs for perforin, granzyme B, Ki-67, or surface molecules.

To stain intracellular cytokines, cells were resuspended in RPMI 1640 medium containing 10% FBS and 1% penicillin/streptomycin (all reagents from Life Technologies), incubated for 30 min at 37 °C, and then stimulated for 4 h at 37 °C with phorbol 12-myristate 13-acetate (PMA; 50 ng/mL) and ionomycin (1 μg/mL) (both reagents from Sigma-Aldrich, St. Louis, MO, USA) in the presence of Golgistop® (BD Biosciences).

After being stained with the appropriate Abs, the cells were analyzed on a BD LSRFortessa™ (BD Biosciences) instrument with FACSDiva™ software, and data were analyzed using FlowJo® software (TreeStar, Ashland, OR, USA).

Statistical analysis {#sec0025}
--------------------

All laboratory data are expressed as the mean ± standard error of the mean (SEM). Data were compared using the two-tailed Mann--Whitney *U* test or Wilcoxon signed rank test. In all analyses, *P*  \< 0.05 was considered to indicate statistical significance. All analyses were performed using PASW for Windows (version 25.0; SPSS Inc., Chicago, IL, USA) and all graphs were plotted using GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA, USA).

Results {#sec0030}
=======

Patients and samples {#sec0035}
--------------------

Four severe and eight mild cases were included in this study. Median (range) ages in severe and mild groups were 62 (35--82) and 55 (25--79), respectively (*P*  = 0.552). Male proportions were 50.0% (2/4) and 25.0% (2/8) in these groups (*P*  = 0.547). All of them had no prior signs of immunodeficiency. PBMCs of one severe patient were available only at his third week of illness. Clinical and laboratory characteristics when the first- and third-week samples were collected are summarized in [Table 1](#tbl0005){ref-type="table"} .Table 1Clinical and laboratory characteristics of patients in mild and severe groups.Table 1Mild (*n* = 8)Severe (*n* = 4)*P*Male, n (%)2 (25.0)2 (50.0)0.547Age, median years (range)55 (25--79)62 (35--82)0.552White blood cells, cells/mm^3^, median (range) At week 14125 (2780--6500)5210 (3160--8760)0.540 At week 35080 (4220--7750)7535 (3900--14,180)0.396Hemoglobin, g/dL, median (range) At week 113.5 (11.0--16.0)12.0 (11.0--13.1)0.179 At week 312.0 (11.5--15.0)11.7 (9.0--13.0)0.218Platelets, 1000 cells/mm^3^, median (range) At week 1192 (159--396)263 (166--316)0.307 At week 3237 (185--386)317 (210--459)0.234C-reactive protein, mg/dL, median (range) At week 10.7 (0.0--6.6)1.6 (1.6--14.9)0.041 At week 30.1 (0.0--0.7)7.6 (4.5--28.5)0.006LDH, U/L, median (range) At week 1162 (131--350)439 (223--455)0.053 At week 3163 (129--411)393 (254--561)0.023Ct for E gene from NP swabs, median (range) At week 124.78 (17.3--40.0)29.3 (26.8--32.1)0.221 At week 339.3 (29.1--40.0)35.4 (29.7--40.0)0.725Oxygen therapy-- Start date, day of illness, median (range)--9 (4--14)-- At week 3, median (range)--6 L/min (4 L/min to MV)-- Peak oxygen demand, median (range)--6 L/min (6 L/min to MV)--[^2]

Median \[range\] cycle threshold (Ct) values of quantitative real-time reverse transcription polymerase chain reaction for SARS-CoV-2 envelope (E) gene from nasopharyngeal swabs in severe patients were increased from 29.3 \[26.8--32.1\] at the first week to 35.4 \[29.7--40.0\] (negative results were converted to 40) at the third week, respectively. While all the patients in the severe group had minimal oxygen requirements at the first week, they all had worsened pneumonic infiltration and were receiving oxygen therapy when the third week samples were collected (three nasal prongs 4--6 L/min and one mechanical ventilation). All four severe patients and three of eight mild patients received lopinavir/ritonavir; however, corticosteroid was not administered in all patients during the course. No 30-day in-hospital mortality was noted among those patients.

PBMCs from five healthy volunteers were also analyzed. Their median (range) age was 35 (28--47), and three of them (60%) were male. Their results are described in [Table 2](#tbl0010){ref-type="table"} and shown in Figures as gray boxes to indicate their interquartile range.Table 2Leukocyte populations and characterization of CD4^+^ and CD8^+^ T cells at the first week of illness according to the severity.Table 2Severe cases (*n* = 3)Mild cases (*n* = 8)Healthy controls (*n* = 5)*PSevere vs. mildSevere vs. controlsMild vs. controls*White blood cells (/μL)5710.0 (± 1635.8)4541.3 (± 568.5)6422.5 (± 1260.0)0.5400.7240.174Neutrophil (/μL)4134.7 (± 1453.8)2803.9 (± 543.5)3581.0 (± 996.4)0.3071.0000.396Monocyte (/μL)429.3 (± 127.0)414.6 (± 51.5)486.5 (± 103.1)1.0000.7240.497Lymphocyte (/μL)1131.7 (± 112.6)1256.3 (± 130.4)2214.5 (± 380.6)0.6830.0340.011CD4^+^ T cells (/μL)306.2 (± 79.0)435.5 (± 57.5)768.3 (± 236.1)0.3070.0770.062 Ki-67^+^ CD4^+^ (%)4.1 (± 1.3)4.0 (± 1.2)0.8 (± 0.2)0.6830.0250.008 HLA-DR^+^CD4^+^ (%)2.2 (± 1.1)2.9 (± 0.9)0.6 (± 0.3)0.6830.1010.013 PD-1^+^CD4^+^ (%)1.4 (±  0.4)0.8 (± 0.3)0.2 (± 0.1)0.1530.0250.057 CD38^+^CD4^+^ (%)1.0 (± 1.0)0.3 (± 0.2)0.1 (± 0.0)0.5400.8810.079 FoxP3^+^CD4^+^ (%)7.1 (± 1.2)6.6 (± 0.5)7.9 (± 0.8)0.8380.6550.242 Perforin^+^CD4^+^ (%)7.0 (± 1.2)6.9 (± 3.1)6.1 (± 2.0)0.2210.6550.770 Granzyme B^+^CD4^+^ (%)7.8 (± 1.8)11.6 (± 3.6)10.0 (± 1.8)0.6830.2970.464 IFN-γ^+^CD4^+^ (%)4.7 (± 1.3)5.8 (± 1.2)8.8 (± 1.9)0.8380.1570.126 IL-2^+^CD4^+^ (%)23.2 (± 10.5)20.2 (± 4.9)14.0 (± 3.4)0.6830.4560.558 IL-4^+^CD4^+^ (%)3.4 (± 1.0)3.2 (± 0.6)2.1 (± 0.6)0.8380.2970.242 IL-17^+^CD4^+^ (%)0.5 (± 0.2)0.4 (± 0.1)0.2 (± 0.1)0.8380.2970.188CD8^+^ T cells (/μL)143.2 (± 13.1)296.1 (± 60.9)660.5 (± 132.4)0.1020.0340.042 Ki-67^+^CD8^+^ (%)6.4 (± 1.8)8.7 (± 3.6)0.8 (± 0.1)0.6830.0250.003 HLA-DR^+^CD8^+^ (%)2.2 (± 1.1)6.0 (± 2.4)0.2 (± 0.1)0.5400.0250.013 PD-1^+^CD8^+^ (%)1.0 (± 0.2)1.1 (± 0.4)0.2 (± 0.1)0.4140.0250.013 CD38^+^CD8^+^ (%)5.9 (± 5.2)1.6 (± 0.4)0.4 (± 0.2)0.8380.2970.057 Perforin^+^CD8^+^ (%)54.2 (± 7.1)40.0 (± 5.7)39.9 (± 7.7)0.1020.1800.884 Granzyme B^+^CD8^+^ (%)65.2 (± 2.9)53.3 (± 7.0)46.2 (± 7.2)0.5400.0530.558 IFN-γ^+^CD8^+^ (%)12.7 (± 7.8)13.2 (± 2.8)17.5 (± 1.5)0.5400.4800.174 IL-2^+^CD8^+^ (%)11.0 (± 8.4)7.6 (± 2.4)5.5 (± 1.5)1.0000.8810.884 IL-4^+^CD8^+^ (%)8.0 (± 6.5)4.4 (± 0.9)1.9 (± 0.8)0.8380.2970.079 IL-17^+^CD8^+^ (%)0.2 (± 0.1)0.2 (± 0.1)0.1 (± 0.0)0.5400.2970.019Effector memory CD8^+^ (%)77.1 (± 4.1)75.5 (± 6.2)69.9 (± 6.8)0.8380.4560.420 IL-7Rα^high^ (%)20.6 (± 4.4)30.9 (± 3.9)32.1 (± 7.0)0.1520.2970.660 IL-7Rα^low^ (%)79.0 (± 4.4)68.7 (± 3.9)65.6 (± 6.6)0.1530.1010.661[^3]

Leukocyte populations in peripheral blood {#sec0040}
-----------------------------------------

In general, neutropenia or lymphopenia can occur during the early stages of respiratory viral infection ([@bib0015], [@bib0025]). Thus, to confirm how they change in COVID-19 patients, we analyzed the changes in leukocyte subpopulations at the first week and third week of illness. The absolute numbers (cells/μL) of lymphocytes were comparable between the severe and mild groups in both time points, although they were lower than that from healthy controls ([Table 2](#tbl0010){ref-type="table"} and [Figure 1](#fig0005){ref-type="fig"} A). Although CD4^+^ and CD8^+^ T cell counts tended to be lower in the severe group than in the mild group at the third week of illness (mean ± standard error of the mean \[SEM\]; CD4^+^ T cell, 396.5 ± 101.9 in the severe group *vs.* 684.3 ± 82.0 in the mild group, *P*  = 0.062; CD8^+^ T cell, 250.9 ± 50.1 in the severe group *vs.* 445.0 ± 76.1 in the mild group, *P*  = 0.174, [Figure 1](#fig0005){ref-type="fig"}B), there was no difference at the first week ([Table 2](#tbl0010){ref-type="table"}). This raises the question of whether there are significant changes in immune-cell subsets according to different clinical courses.Figure 1Leukocyte populations and CD4^+^ and CD8^+^ T cell counts and Ki-67 expressions at the third week of illness in 12 patients with COVID-19 according to severity. (A) The counts (cells/μL) of neutrophils, lymphocyte, and monocytes in severe (*n* = 4, open circle) or mild cases (*n* = 8, closed circle). (B) Frequencies and counts (cells/μL) of CD4^+^ and CD8^+^ T cells. (C) Ki-67 expressions in CD4^+^ and CD8^+^ T cells. (D) Representative dot plots show the identification of Ki-67^+^, HLA-DR^+^, PD-1^+^, or CD38^+^ cells in CD4^+^ (1st line of each panel) or CD8^+^ (2nd line of each panel) T cells in severe (upper panels) or mild (lower panels) cases. Bars denote mean values. Gray boxes represent interquartile ranges of healthy controls.Figure 1

Expression of markers for proliferation and activation of T-cell subsets {#sec0045}
------------------------------------------------------------------------

To investigate dynamics of the antigen-specific T cells according to severity of COVID-19, we determined the frequency of proliferating or activated T cells in the two groups. Although we could not attempt staining with peptide-MHC tetramer ([@bib0005]) for SARS-CoV-2, it was thought that analysis of these markers would sufficiently trace antigen-specific T cells as previously known ([@bib0070], [@bib0095]). Although frequencies (%) of Ki-67^+^ CD4^+^ and CD8^+^ T cells were higher than those from healthy controls in both groups, they were significantly higher in the severe group than in the mild group (mean ± SEM, the severe group *vs.* the mild group; Ki-67^+^ in CD4^+^ T cells, 6.7 ± 1.9 *vs.* 2.4 ± 0.3, *P*  = 0.011; Ki-67^+^ in CD8^+^ T cells, 10.9 ± 1.8 *vs.* 4.3 ± 1.1, *P*  = 0.027; [Figure 1](#fig0005){ref-type="fig"}C and D), signifying a higher rate of T-cell turnover in the severe group.

We also examined frequencies (%) of HLA-DR, PD-1, and CD38 as makers of activated T cells. Although they tended to be higher in both groups than in the healthy control group, there were no differences at the first week between the two groups ([Table 2](#tbl0010){ref-type="table"}). However, activated T cells tended to be higher in the severe group than in the mild group at the third week, especially in terms of PD-1 expression (mean ± SEM, the severe group *vs.* the mild group; HLA-DR^+^ in CD4^+^ T cell, 4.3 ± 1.9 *vs.* 2.4 ± 0.4, *P*  = 0.396; HLA-DR^+^ in CD8^+^ T cells, 3.8 ± 0.9 *vs.* 3.7 ± 1.9, *P*  = 0.174; PD-1^+^ in CD4^+^ T cells, 2.3 ± 0.8 *vs.* 0.4 ± 0.1, *P*  = 0.007; PD-1^+^ in CD8^+^ T cells, 1.4 ± 0.2 *vs.* 0.6 ± 0.3, *P*  = 0.042; CD38^+^ in CD4^+^ T cells, 0.7 ± 0.6 *vs.* 0.3 ± 0.2, *P*  = 0.234; CD38^+^ in CD8^+^ T cells, 3.0 ± 1.5 *vs.* 1.7 ± 0.9, *P*  = 0.234; [Figure 2](#fig0010){ref-type="fig"} A). Taken together, the severe group showed a higher degree of proliferation and activation of T cells.Figure 2Expressions of activation markers and FoxP3^+^ CD4^+^ T cells at the third week of illness according to severity. (A) HLA-DR, PD-1, and CD38 expressions in CD4^+^ and CD8^+^ T cells, in severe (*n* = 4, open circle) and mild cases (*n* = 8, closed circle). (B) Frequencies of FoxP3^+^CD4^+^ T cells and representative dot plots showing the identification of the population. Bars denote mean values. Gray boxes represent interquartile ranges of healthy controls.Figure 2

Given the fact that regulatory T cells (Tregs), FoxP3^+^CD4^+^ T cells, suppress activation, proliferation and cytokine production of CD4^+^ and CD8^+^ T cells ([@bib0085]), the possibility was raised of whether excessive T-cell activation in the severe group could be due to a decrease in the number of Tregs or due to a decrease in inhibitory capacity. To address this, we measured frequency of FoxP3^+^CD4^+^ Tregs. As a result, although statistically not significant, frequencies (%) of FoxP3^+^CD4^+^ Tregs tended to be lower in severe patients at the third week of illness (mean ± SEM, 5.9 ± 0.6 in the severe group *vs.* 7.4 ± 0.9 in the mild group, *P*  = 0.131, [Figure 2](#fig0010){ref-type="fig"}B), suggesting that the overall inhibitory capacity for effector T cells would be reduced.

Expressions of effector granules and cytokines {#sec0050}
----------------------------------------------

Furthermore, we examined the expression levels of effector molecules which could eradicate infected cells as well as cause tissue damage ([@bib0020], [@bib0055], [@bib0060]). Thus, we examined the expression of effector granules and cytokines to reveal the consequences of increased T-cell activation at the third week of illness. Frequencies (%) of perforin and granzyme B expression in both CD4^+^ and CD8^+^ T cells were higher in the severe group than in the mild group (mean ± SEM, the severe group *vs.* the mild group; perforin^+^ in CD4^+^ T cells, 7.0 ± 2.2 *vs.* 2.3 ± 1.2, *P*  = 0.038; granzyme B^+^ in CD4^+^ T cells, 9.0 ± 3.0 *vs.* 6.2 ± 1.9, *P*  = 0.571; perforin^+^ in CD8^+^ T cells, 47.6 ± 1.4 *vs.* 26.5 ± 4.8, *P*  = 0.008; granzyme B^+^ in CD8^+^ T cells, 68.1 ± 7.4 *vs.* 40.0 ± 5.8, *P*  = 0.008; [Figure 3](#fig0015){ref-type="fig"} A). Proportions (%) of IL-7Rα^low^ effector memory (CCR7^−^CD45RA^+/−^) CD8^+^ T cells, which are known for high perforin and granzyme B expression ([@bib0055]) ([Figure 3](#fig0015){ref-type="fig"}A, lower panel), were significantly higher in the severe group than in the mild group (mean ± SEM, 78.5 ± 3.9 in the severe group *vs.* 62.8 ± 3.1 in the mild group, *P*  = 0.023; [Figure 3](#fig0015){ref-type="fig"}B), implying a higher cytotoxic potential in the severe groups at the third week of illness. Similarly, increased IL-7Rα^low^ effector memory CD8^+^ T cells might be secondary to the expansion of effector memory CD8^+^ T cells (Supplementary Figure S1), which is known to be produced by prolonged antigenic stimulation ([@bib0040]).Figure 3Effector granules or cytokine expressions at the third week of illness according to severity. (A) Perforin or granzyme B expressions in severe (*n* = 4, open circle) and mild cases (*n* = 8, closed circle) and representative dot plots showing the identification of perforin^+^, granzyme B^+^, IL-7Rα^high^, or IL-7Rα^low^ cells in CD4^+^ or CD8^+^ T cells in severe (upper panels) or mild (lower panels) cases. (B) Frequencies of IL-7Rα^low^ effector memory (CCR7-CD45RA^+/−^) CD8**^+^** T cells and representative histograms. (C) IFN-γ, IL-2, IL-4, and IL-17 expressions in CD4^+^ and CD8^+^ T cells and representative dot plots showing the identification of IFN-γ**^+^**, IL-2**^+^**, IL-4**^+^**, and IL-17**^+^** cells in CD4^+^ or CD8^+^ T cells in severe (upper panels) or mild (lower panels) cases. Bars denote mean values. Gray boxes represent interquartile ranges of healthy controls.Figure 3

Compared to the difference in cytotoxic molecules, expression levels of IFN-γ, IL-2, IL-4, and IL-17 were comparable between the two groups at both time points ([Table 2](#tbl0010){ref-type="table"} and [Figure 3](#fig0015){ref-type="fig"}C). It is presumed that the effector cytokine expression alone did not significantly affect severity of COVID-19.

Lack of T-cell contraction in severe COVID-19 groups {#sec0055}
----------------------------------------------------

Interestingly, when we compared the above immune responses between the first and third weeks of illness in each group, the mild group tended to show substantial reduction of Ki-67, PD-1, perforin, and granzyme B expressions compared to those in the severe group ([Figure 4](#fig0020){ref-type="fig"} ). In contrast, the expression levels of those molecules in the severe group did not decrease or even tended to increase at the third week. The proportion of IL-7Rα^low^ effector memory CD8^+^ T cells was not reduced in the severe group. Since cells expressing such markers are believed to represent cells that have recently been stimulated with antigen ([@bib0050], [@bib0070], [@bib0095]), these findings imply a lack of cytotoxic T-cell contraction or delayed hyperactivation of T cells in the severe group.Figure 4Temporal changes of cell-mediated immune responses in 11 patients with COVID-19 according to severity. Frequencies of Ki-67^+^, PD-1^+^, perforin^+^, granzyme B^+^ CD8^+^ T cells, and IL-7Rα^low^ effector memory CD8^+^ T cells in severe (*n* = 3) or mild (*n* = 8) cases from the first week (closed circle) to the third week (open circle).Figure 4

Discussion {#sec0060}
==========

Therapeutic strategies for severe COVID-19 should be developed in a timely manner, and must be preceded by an understanding of its immunopathogenesis. In this study, we observed higher turnover and activation of T cells and higher expression of cytotoxic effectors such as perforin and granzyme B in the severe group than in the mild group at the third week of illness. This might be due to the lack of cytotoxic T-cell contraction, and it is possible that such an immune response contributed to clinical deterioration at the second or third week of illness in severe COVID-19 patients.

Median days from symptom onset to dyspnea, development of acute respiratory distress syndrome, and ICU admission in COVID-19 patients were 7, 12, and 12 days, respectively ([@bib0125], [@bib0135]). Interestingly, viral load of SARS-coronavirus-2 (SARS-CoV-2) peaks during the first 3--5 days of illness and declines thereafter ([@bib0065], [@bib0145]). Although initial viral loads are higher in severe cases, they also decline after the early peak ([@bib0065]). This viral shedding kinetics of COVID-19 is markedly different from that of MERS, which peaks during the second week of illness ([@bib0075]). Such a time lag between the peak of viral load and the clinical deterioration implies the importance of immune response in the pathogenesis of severe COVID-19. And persistent or delayed hyperactivation of cytotoxicity could be explained in CD8^+^ T cells as well as CD4^+^ T cells ([@bib0035]). Although there is no difference in the expression of cytokines between the severe and the mild groups, if IFN-γ-producing CD8^+^ T (Tc1) cells express highly cytotoxic molecules such as perforin and granzyme B, they may exhibit high cytotoxicity in the severe group.

There were a few studies that explored CMI response in COVID-19 ([@bib0080], [@bib0100], [@bib0120]). Although they reported activation of CD4^+^ and CD8^+^ T cells, decreased numbers of T cells, or high concentrations of cytotoxic granules, and some are consistent with the results of the present study, data on severe COVID-19 patients or temporal changes of CMI response were lacking ([@bib0080], [@bib0100], [@bib0120]). We believe that our results, focusing on immune responses characterizing severe COVID-19 cases with a temporal consideration, may elucidate the pathogenesis of severe COVID-19.

In addition, unknown factors that may affect the immune response could be related to severe COVID-19. In this regard, Cornberg et al. suggested an important possibility that the degree of antigen exposure can regulate the balance between protective immunity and immunopathology by presenting the medium-dose virus-induced immunopathology and T-cell exhaustion by massive virus exposure ([@bib0030]). It seems consistent with the development of severe COVID-19, which clinically deteriorates when viral loads are declining. In addition, activated bystander CD8^+^ T cells induced by IL-15 can participate in protective immunity ([@bib0045], [@bib0090]), but they also can cause excessive tissue damage because of its lack of specificity for the pathogen ([@bib0060]). In this regard, an increase in IL-7Rα^low^ effector memory CD8^+^ T cells, which are known to express activating receptors of natural killer cells and have cytotoxic ability through this receptor ([@bib0020]), with high expression of cytotoxic molecules in severe groups suggests that there is a possibility of CMI response-mediated tissue damage. Nonetheless, further studies are needed to explore whether these factors contribute to pathogenesis of severe COVID-19.

There are several therapeutic agents for the treatment of COVID-19. When considering the viral shedding kinetics ([@bib0065], [@bib0145]), antiviral agents such as lopinavir/ritonavir, remdesivir, or hydroxychloroquine ([@bib0010], [@bib0105], [@bib0130]) may be effective during the first week of illness when the virus is actively replicating. In contrast, our study suggests that immune-modulating agents may be effective during the second week of illness.

This study has some limitations. First, the number of patients analyzed in this study was small. Although we could find important differences of CMI responses in severe and mild COVID-19 cases which were consistent with clinical course, it would be better for this to be verified in a larger cohort. Second, it would be desirable to have more time points to be examined to elucidate the exact temporal changes of such responses or when the persistent cytotoxic T-cell activity returns to normal in severe cases. Finally, the potential immunomodulatory effects of lopinavir/ritonavir could not be adjusted because the drug was prescribed to all severe patients in this study.

Conclusion {#sec0065}
==========

We observed a higher degree of proliferation, activation, and cytotoxicity of T-cells accompanying the lack of cytotoxic T-cell contraction in severe COVID-19 cases than in mild cases, which may contribute to the progression of pneumonia during the second week of illness.
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